172 related articles for article (PubMed ID: 37740857)
1. Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study.
Sowlati M; Morariu SH; Orzan O; Veraldi S; Dodiuk-Gad RP; Orasan RI; Gainaru C
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2669-2679. PubMed ID: 37740857
[TBL] [Abstract][Full Text] [Related]
2. Topical Application of a Formulation Containing Pea Proteins and Xyloglucan in Adult Patients with Atopic Dermatitis: A Double-blind, Parallel, Randomized, Placebo-controlled, Multicenter Study.
Sowlati M; Orzan OA; Morariu SH; Etropolska Z; Veraldi S; Dimitrov S
J Clin Aesthet Dermatol; 2023 Jul; 16(7):35-41. PubMed ID: 37560506
[TBL] [Abstract][Full Text] [Related]
3. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
[TBL] [Abstract][Full Text] [Related]
4. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF; Gebauer K; Spelman L; Zane LT
J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
[TBL] [Abstract][Full Text] [Related]
5. Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis.
Campolo M; Casili G; Paterniti I; Filippone A; Lanza M; Ardizzone A; Scuderi SA; Cuzzocrea S; Esposito E
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32438777
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
8. A comparative randomized clinical trial evaluating the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment of atopic dermatitis in children.
Mohamed AA; El Borolossy R; Salah EM; Hussein MS; Muharram NM; Elsalawy N; Khalil MG; Mahmoud MO; El-Amir RY; Elsanhory HMA; Ahmed N; Adaroas AS; Montaser M; El Kholy AA
Front Pharmacol; 2023; 14():1202325. PubMed ID: 37799965
[No Abstract] [Full Text] [Related]
9. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
10. SNG100, a novel topical treatment for moderate atopic dermatitis, in patients aged 6 years or older: A randomised, double-blind, active-controlled trial.
Samuelov L; Shemer A; Greenberger S; Ziv I; Friedman D; Yacoby-Zeevi O; Dodiuk-Gad R; Ramot Y; Murad S; Sprecher E
Skin Health Dis; 2023 Dec; 3(6):e293. PubMed ID: 38047249
[TBL] [Abstract][Full Text] [Related]
11. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
[TBL] [Abstract][Full Text] [Related]
12. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study.
Udompataikul M; Limpa-o-vart D
J Drugs Dermatol; 2012 Mar; 11(3):366-74. PubMed ID: 22395588
[TBL] [Abstract][Full Text] [Related]
13. Validation of five patient-reported outcomes for atopic dermatitis severity in adults.
Silverberg JI; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Ong PY; Fuxench ZC; Simpson EL
Br J Dermatol; 2020 Jan; 182(1):104-111. PubMed ID: 30972740
[TBL] [Abstract][Full Text] [Related]
14. A new topical treatment of atopic dermatitis in pediatric patients based on Ficus carica L. (Fig): A randomized, placebo-controlled clinical trial.
Abbasi S; Kamalinejad M; Babaie D; Shams S; Sadr Z; Gheysari M; Askari VR; Rakhshandeh H
Complement Ther Med; 2017 Dec; 35():85-91. PubMed ID: 29154073
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
16. Impact of daily use of emollient 'plus' on corticosteroid consumption in patients with atopic dermatitis: An open, randomized controlled study.
Zelenkova H; Kerob D; Salah S; Demessant-Flavigny AL
J Eur Acad Dermatol Venereol; 2023 Jun; 37 Suppl 5():27-34. PubMed ID: 37092256
[TBL] [Abstract][Full Text] [Related]
17. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
Schlessinger J; Shepard JS; Gower R; Su JC; Lynde C; Cha A; Ports WC; Purohit V; Takiya L; Werth JL; Zang C; Vlahos B;
Am J Clin Dermatol; 2020 Apr; 21(2):275-284. PubMed ID: 32212104
[TBL] [Abstract][Full Text] [Related]
18. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.
Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
Ann Allergy Asthma Immunol; 2020 Jul; 125(1):78-83. PubMed ID: 32199977
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
